Efanesoctocog Alfa Not Cost-Effective for Prophylaxis in Hemophilia A

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 28, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, April 28, 2025 -- For U.S. patients with severe hemophilia A, prophylaxis with efanesoctocog alfa is neither conventionally nor distributionally cost-effective, according to a study published online April 22 in the Annals of Internal Medicine.

Satoko Ito, M.D., Ph.D., from the Yale School of Medicine in New Haven, Connecticut, and colleagues examined the conventional and distributional cost-effectiveness of prophylaxis with efanesoctocog alfa versus standard-care factor VIII (standard and extended half-life) in the United States using a Markov model.

The researchers found that efanesoctocog alfa and standard-care factor VIII accrued 19.7 and 14.6 discounted lifetime quality-adjusted life years (QALYs) at costs of $22.1 and $11.2 million, respectively; the incremental cost-effectiveness ratio per QALY was $2.13 million. The distributional cost-effectiveness analysis-derived threshold equity weight was 6.9, which exceeded U.S. equity standards that are commonly used. Across all scenario analyses, the results were consistent. In a sensitivity analysis, the conclusion could only be changed by the price of efanesoctocog alfa. For conventional and distributional cost-effectiveness, efanesoctocog alfa needs to be priced at less than 53 and less than 59 percent of its current price, respectively. In 100 percent of 10,000 probabilistic iterations, standard-care factor VIII was favored.

"Alternative pricing mechanisms, longer-term clinical follow-up data, and studies across additional jurisdictions where efanesoctocog alfa is approved will be critical to understanding the value of this therapy in the context of existing treatment options in the hemophilia A arena," the authors write.

Several authors disclosed ties to relevant organizations.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-04-29 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords